UPCC 26921: A Phase 1a/1b Open-label Dose-Escalation and Expansion Study of TPST-1495 as a Single Agent and in Combination with Pembrolizumab in Subjects with Solid Tumors

Brief description of study

Please refer to Section 4 of the full protocol (Study Objectives and Endpoints) Please refer to Section 4 of the full protocol (Study Objectives and Endpoints) Please refer to Section 4 of the full protocol (Study Objectives and Endpoints)

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Medical Research
  • Age: - 99 Years
  • Gender: All
Updated on 09 Mar 2024. Study ID: 850046
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center